Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice
Authors:
- Linan ChenLCLinan Chen
- Yunmin DingYDYunmin Ding
- Barbara CagniardBCBarbara Cagniard
- Amber D. Van LaarALAmber D. Van Laar
- Amanda MortimerAMAmanda Mortimer
- Wanhao ChiWCWanhao Chi
- Teresa G. HastingsTHTeresa G. Hastings
- Un Jung KangUKUn Jung Kang
- Xiaoxi ZhuangXZXiaoxi Zhuang
Open Access
- 9 January 2008
- journal article
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 28 (2) , 425-433
Abstract
The role of dopamine as a vulnerability factor and a toxic agent in Parkinson's disease (PD) is still controversial, yet the presumed dopamine toxicity is partly responsible for the “DOPA-sparing” clinical practice that avoids usingl-3,4-dihydroxyphenylalanine (l-DOPA), a dopamine precursor, in early PD. There is a lack of studies on animal models that directly isolate dopamine as one determining factor in causing neurodegeneration. To address this, we have generated a novel transgenic mouse model in which striatal neurons are engineered to take up extracellular dopamine without acquiring regulatory mechanisms found in dopamine neurons. These mice developed motor dysfunctions and progressive neurodegeneration in the striatum within weeks. The neurodegeneration was accompanied by oxidative stress, evidenced by substantial oxidative protein modifications and decrease in glutathione. Ultrastructural morphologies of degenerative cells suggest necrotic neurodegeneration. Moreover,l-DOPA accelerated neurodegeneration and worsened motor dysfunction. In contrast, reducing dopamine input to striatum by lesioning the medial forebrain bundle attenuated motor dysfunction. These data suggest that pathology in genetically modified striatal neurons depends on their dopamine supply. These neurons were also supersensitive to neurotoxin. A very low dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (5 mg/kg) caused profound neurodegeneration of striatal neurons, but not midbrain dopamine neurons. Our results provide the firstin vivoevidence that chronic exposure to unregulated cytosolic dopamine alone is sufficient to cause neurodegeneration. The present study has significant clinical implications, because dopamine replacement therapy is the mainstay of PD treatment. In addition, our model provides an efficientin vivoapproach to test therapeutic agents for PD.Keywords
This publication has 51 references indexed in Scilit:
- Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's DiseaseThe Journal of Neuroscience, 2007
- Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s diseaseNeurobiology of Disease, 2007
- Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's diseaseEuropean Journal of Neuroscience, 2006
- α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's ModelsScience, 2006
- Dopamine covalently modifies and functionally inactivates parkinNature Medicine, 2005
- Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathwayThe FASEB Journal, 2005
- Dopamine and L‐dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's diseaseThe FASEB Journal, 2004
- Low-Level Tyrosine Hydroxylase (TH) Expression Allows for the Generation of Stable TH + Cell Lines of Human Neural Stem CellsHuman Gene Therapy, 2004
- Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic NeuronsJournal of Biological Chemistry, 2003
- Control of Memory Formation Through Regulated Expression of a CaMKII TransgeneScience, 1996